Testing for this particular mutation defines the predicted response to this drug. A recent study showed that combination therapy which included cetuximab reduced the risk for metastatic colorectal cancer growth or spread by 15%. KRAS mutation analysis is now therefore a standard of care necessary for all newly diagnosed CRCs.
Tissue that has been decalcified in acid is not suitable.
Bessemer Wing - 2nd Floor
London SE5 9RS
Last updated: 07/08/2015